Skip to content
value.today
Antigenics Inc /de/ logo

Antigenics Inc /de/

Antigenics Inc /de/ is listed today as Agenus Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 10 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Antigenics Inc /de/
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2019$30 MPrivate placement after listing$10 to $50 million

Antigenics Inc /de/: Private sale, Jan 2019

Investors in this round

1 investor had bought by the notice of Feb 1, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alex R. Duncan · Executive Officer
  • Christian R. Cortis · Executive Officer
  • Christine R. Klaskin · Executive Officer
  • Evan R. Kearns · Executive Officer
  • Garo H. Armen · Executive Officer, Director
  • Jennifer R. Buell · Executive Officer
  • Ozer R. Baysal · Executive Officer
  • Allison R. Jeynes-Ellis · Director
  • Brian H. Corvese · Director
  • Timothy R. Wright · Director
  • Ulf H. Wiinberg · Director
  • Wadih H. Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Evan Kearns, Vice President and General Counsel. Source: SEC Form D, newest notice filed Feb 1, 2019. Read the notice at the SEC.

equitySEC
Oct 2018$40 MPrivate placement after listing$10 to $50 million

Antigenics Inc /de/: Private sale, Oct 2018

Investors in this round

2 investors had bought by the notice of Oct 25, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alex R. Duncan · Executive Officer
  • Christian R. Cortis · Executive Officer
  • Christine R. Klaskin · Executive Officer
  • Evan R. Kearns · Executive Officer
  • Garo H. Armen · Executive Officer, Director
  • Jennifer R. Buell · Executive Officer
  • Ozer R. Baysal · Executive Officer
  • Brian H. Corvese · Director
  • Timothy R. Wright · Director
  • Ulf H. Wiinberg · Director
  • Wadih H. Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Evan Kearns, Vice President and General Counsel. Source: SEC Form D, newest notice filed Oct 25, 2018. Read the notice at the SEC.

equitySEC
Feb 2017$60 MPrivate placement after listing$50 to $250 million

Antigenics Inc /de/: Private sale, Feb 2017

Investors in this round

1 investor had bought by the notice of Mar 1, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine M. Klaskin · Executive Officer
  • Garo H. Armen · Executive Officer, Director
  • Karen H. Valentine · Executive Officer
  • Ozer M. Baysal · Executive Officer
  • Robert B. Stein · Executive Officer
  • Brian H. Corvese · Director
  • Shahzad H. Malik · Director
  • Shalini H. Sharp · Director
  • Timothy H. Wright · Director
  • Ulf H. Wiinberg · Director
  • Wadih H. Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Karen H. Valentine, Chief Legal Officer and General Counsel. Source: SEC Form D, newest notice filed Mar 1, 2017. Read the notice at the SEC.

equitySEC
Dec 2015$7 MPrivate placement after listing$2 to $10 million

Antigenics Inc /de/: Private sale, Dec 2015

Investors in this round

17 investors had bought by the notice of Jan 4, 2016: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $42 M offered; $35 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Evan Ballantyne · Executive Officer
  • Christine M. Klaskin · Executive Officer
  • Garo Armen · Executive Officer, Director
  • Karen H. Valentine · Executive Officer
  • Ozer M. Baysal · Executive Officer
  • Robert M. Stein · Executive Officer
  • Brian M. Corvese · Director
  • Shahzad M. Malik · Director
  • Shalini M. Sharp · Director
  • Timothy R. Wright · Director
  • Tom M. Dechaene · Director · No longer a member of the Board of Directors of the Issuer as of January 1, 2016
  • Wadih M. Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by C. Evan Ballantyne, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 4, 2016. Read the notice at the SEC.

equitySEC
Sep 2015$2 MPrivate placement after listing$2 to $10 million

Antigenics Inc /de/: Private sale, Sep 2015

Investors in this round

2 investors had bought by the notice of Sep 23, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Charles Evan Ballantyne · Executive Officer · Chief Financial Officer
  • Christine M. Klaskin · Executive Officer · VP, Finance and Treasurer
  • Garo H. Armen · Executive Officer, Director · President and CEO
  • Karen H. Valentine · Executive Officer · Chief Legal Officer, General Counsel and Secretary
  • Ozer Evan Baysal · Executive Officer · Chief Business Officer
  • Robert R. Stein · Executive Officer · Chief Scientific Officer
  • Brian R. Corvese · Director
  • Shahzad R. Malik · Director
  • Shalini H. Sharp · Director
  • Timothy R. Wright · Director
  • Tom R. Dechaene · Director
  • Wadih R. Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by C. Evan Ballantyne, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 23, 2015. Read the notice at the SEC.

equitySEC
Feb 2015$21 MPrivate placement after listing$10 to $50 million

Antigenics Inc /de/: Private sale, Feb 2015

Investors in this round

8 investors had bought by the notice of Mar 5, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine Klaskin · Executive Officer
  • Garo Armen · Executive Officer, Director
  • Karen Valentine · Executive Officer
  • Ozer Baysal · Executive Officer
  • Robert Stein · Executive Officer
  • Brian Corvese · Director
  • Shahzad Malik · Director
  • Shalini Sharp · Director
  • Timothy Wright · Director
  • Tom Dechaene · Director
  • Wadih Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes warrants to purchase up to 1,400,000 shares of common stock of Agenus Inc. at an exercise price of $5.10 per share.”

Signed by Karen H. Valentine, Vice President and General Counsel. Source: SEC Form D, newest notice filed Mar 5, 2015. Read the notice at the SEC.

debt, optionsSEC
Feb 2015$35 MPrivate placement after listing$10 to $50 million

Antigenics Inc /de/: Private sale, Feb 2015

Investors in this round

1 investor had bought by the notice of Mar 5, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine Klaskin · Executive Officer
  • Garo Armen · Executive Officer, Director
  • Karen Valentine · Executive Officer
  • Ozer Baysal · Executive Officer
  • Robert Stein · Executive Officer
  • Brian Corvese · Director
  • Shahzad Malik · Director
  • Shalini Sharp · Director
  • Timothy Wright · Director
  • Tom Dechaene · Director
  • Wadih Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Karen H. Valentine, Vice President and General Counsel. Source: SEC Form D, newest notice filed Mar 5, 2015. Read the notice at the SEC.

equitySEC
Apr 2013$5 MPrivate placement after listing$2 to $10 million

Antigenics Inc /de/: Private sale, Apr 2013

Investors in this round

3 investors had bought by the notice of Apr 25, 2013: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine Klaskin · Executive Officer
  • Garo Armen · Executive Officer, Director
  • Karen Valentine · Executive Officer
  • Kerry Wentworth · Executive Officer
  • Brian Corvese · Director
  • Shalini Sharp · Director
  • Timothy Wright · Director
  • Tom Dechaene · Director
  • Wadih Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Garo H. Armen, Ph.D., Chief executive officer and chairman of the board. Source: SEC Form D, newest notice filed Apr 25, 2013. Read the notice at the SEC.

debt, optionsSEC
Aug 2009$10 MPrivate placement after listing$10 to $50 million

Antigenics Inc /de/: Private sale, Aug 2009

Investors in this round

4 investors had bought by the notice of Aug 13, 2009: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$650,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine M Klaskin · Executive Officer
  • Garo H. Armen · Executive Officer, Director
  • Karen Valentine · Executive Officer
  • Kerry A Wentworth · Executive Officer
  • Shalini Sharp · Executive Officer
  • Brian Corvese · Director
  • Hyam I Levitsky, M. D. · Director
  • John Hatsopoulos · Director
  • Timothy Rothwell · Director
  • Timothy Wright · Director
  • Tom Dechaene · Director
  • Wadih Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Rodman & Renshaw, LLC (CRD 16415) · broker-dealer Rodman & Renshaw, LLC (CRD 16415) · New York, NySold in no state named

Signed by Christine M. Klaskin, VP, Finance. Source: SEC Form D, newest notice filed Aug 13, 2009. Read the notice at the SEC.

equity, optionsSEC
Aug 2009$10 MPrivate placement after listing$10 to $50 million

Antigenics Inc /de/: Private sale, Aug 2009

Investors in this round

1 investor had bought by the notice of Aug 13, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$600,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christine M Klaskin · Executive Officer
  • Garo H Armen · Executive Officer, Director
  • Karen Valentine · Executive Officer
  • Kerry A Wentworth · Executive Officer
  • Shalini Sharp · Executive Officer
  • Brian Corvese · Director
  • Hyam I Levitsky, M.D · Director
  • John Hatsopoulos · Director
  • Timothy Rothwell · Director
  • Timothy Wright · Director
  • Tom Dechaene · Director
  • Wadih Jordan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Rodman & Renshaw, LLC (CRD 16415) · broker-dealer Rodman & Renshaw, LLC (CRD 16415) · New York, NySold in no state named

Signed by Christine M. Klaskin, VP, Finance. Source: SEC Form D, newest notice filed Aug 13, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Agenus Inc., its revenue in fiscal 2025 came from these product and service lines: Non-Cash Revenue Related to the Sale of Future Royalties $108.59 million (95%), Non-cash royalties $108.59 million (95%), Pre-Commercial Product Revenue $4.24 million (4%), Service Revenue $1.04 million (1%), Other services $1.04 million (1%).

    Annual report (SEC XBRL) · Dec 2025

  • Antigenics Inc /de/ chose not to state its revenue in its newest notice of a funding round (Feb 2019).

    SEC Form D · Feb 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2019

Products and services#

No products or services of Antigenics Inc /de/ are on record.

Investors#

No investor of Antigenics Inc /de/ is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Agenus Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Antigenics Inc /de/
NameRoleNamed in
Alex R. DuncanExecutive officerFeb 2019
Christian R. CortisExecutive officerFeb 2019
Christine R. KlaskinExecutive officerFeb 2019
Evan R. KearnsExecutive officerFeb 2019
Garo H. ArmenExecutive officerFeb 2019
Jennifer R. BuellExecutive officerFeb 2019
Ozer R. BaysalExecutive officerFeb 2019
Christine M. KlaskinExecutive officerMar 2017
Karen H. ValentineExecutive officerMar 2017
Ozer M. BaysalExecutive officerMar 2017
Robert B. SteinExecutive officerMar 2017
Charles Evan BallantyneExecutive officerJan 2016
Garo ArmenExecutive officerJan 2016
Robert M. SteinExecutive officerJan 2016
Ozer Evan BaysalChief Business OfficerSep 2015
Robert R. SteinChief Scientific OfficerSep 2015
Christine KlaskinExecutive officerMar 2015
Karen ValentineExecutive officerMar 2015
Ozer BaysalExecutive officerMar 2015
Robert SteinExecutive officerMar 2015
Kerry WentworthExecutive officerApr 2013
Christine M KlaskinExecutive officerAug 2009
Garo H ArmenExecutive officerAug 2009
Kerry A WentworthExecutive officerAug 2009
Shalini SharpExecutive officerAug 2009
Allison R. Jeynes-EllisDirectorFeb 2019
Brian H. CorveseDirectorFeb 2019
Garo H. ArmenDirectorFeb 2019
Timothy R. WrightDirectorFeb 2019
Ulf H. WiinbergDirectorFeb 2019
Wadih H. JordanDirectorFeb 2019
Shahzad H. MalikDirectorMar 2017
Shalini H. SharpDirectorMar 2017
Timothy H. WrightDirectorMar 2017
Brian M. CorveseDirectorJan 2016
Garo ArmenDirectorJan 2016
Shahzad M. MalikDirectorJan 2016
Shalini M. SharpDirectorJan 2016
Tom M. DechaeneNo longer a member of the Board of Directors of the Issuer as of January 1, 2016Jan 2016
Wadih M. JordanDirectorJan 2016

About

Biotechnology company.

Went public since 2000. Its SEC number is that of a company listed on a stock exchange.